



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) **EP 1 145 717 A3**

(12) **EUROPEAN PATENT APPLICATION**

(88) Date of publication A3:
14.08.2002 Bulletin 2002/33

(51) Int Cl.7: **A61K 31/64**, A61K 31/4545,
A61K 45/06, A61P 3/10
// (A61K31/64, 31:4545)

(43) Date of publication A2:
17.10.2001 Bulletin 2001/42

(21) Application number: **01303020.0**

(22) Date of filing: **30.03.2001**

(84) Designated Contracting States:
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE TR**
Designated Extension States:
AL LT LV MK RO SI

(72) Inventors:
• **Fryburg, David Albert
Groton, Connecticut 06340 (US)**
• **Parker, Janice Catherine
Groton, Connecticut 06340 (US)**

(30) Priority: **13.04.2000 US 196728**

(74) Representative: **Wood, David John et al
PFIZER LIMITED,
European Patents Department,
Ramsgate Road,
Sandwich, Kent CT13 9NJ (GB)**

(71) Applicant: **Pfizer Products Inc.
Groton, Connecticut 06340 (US)**

(54) **Synergistic effect of a sulfonylurea and/or non-sulfonylurea K plus ATP channel blocker, and a phosphodiesterase 3 type inhibitor**

(57) The invention relates to the use of a synergistic amount of: 1) a sulfonylurea, a non-sulfonylurea K⁺ ATP channel blocker, or a sulfonylurea and a non-sulfonylurea K⁺ ATP channel blocker; and 2) a cAMP phosphodiesterase type 3 inhibitor; for the manufacture of medicaments for treating or preventing non-insulin dependent diabetes mellitus, insulin resistance, Syndrome X, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic cardiomyopathy, polycystic ovary syndrome, cataracts, hyperglycemia, or impaired glucose tolerance. The present invention also provides kits and pharmaceutical compositions that comprise: 1) a sulfonylurea, a non-sulfonylurea K⁺ATP channel blocker, or a sulfonylurea and a non-sulfonylurea K⁺ ATP

channel blocker; and 2) a cAMP phosphodiesterase type 3 inhibitor. The present invention also relates to kits and pharmaceutical compositions that comprise 1) a sulfonylurea, a non-sulfonylurea K⁺ ATP channel blocker, or a sulfonylurea and a non-sulfonylurea K⁺ ATP channel blocker; 2) a cAMP phosphodiesterase type 3 inhibitor; and 3) an additional compound useful for the treatment of non-insulin dependent diabetes mellitus, insulin resistance, Syndrome X, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic cardiomyopathy, polycystic ovary syndrome, cataracts, hyperglycemia, or impaired glucose tolerance.

EP 1 145 717 A3



European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT

Application Number

which under Rule 45 of the European Patent Convention shall be considered, for the purposes of subsequent proceedings, as the European search report

EP 01 30 3020

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
Y	WO 98 36755 A (WARNER LAMBERT CO ; WHITCOMB RANDALL W (US)) 27 August 1998 (1998-08-27) * abstract *	1-25	A61K31/64 A61K31/4545 A61K45/06 A61P3/10 //(A61K31/64, 31:4545)
Y	PARKER J C ET AL: "EFFECT OF CYCLIC AMP PHOSPHODIESTERASE INHIBITORS ON INSULIN SECRETION AND GLYCEMIA" DIABETOLOGIA, BERLIN, DE, vol. 39, no. SUPPL 1, 1 September 1996 (1996-09-01), page A225 XP001061977 ISSN: 0012-186X * abstract *	1-25	
			TECHNICAL FIELDS SEARCHED (Int.Cl.7)
			A61K A61P
INCOMPLETE SEARCH			
<p>The Search Division considers that the present application, or one or more of its claims, does/do not comply with the EPC to such an extent that a meaningful search into the state of the art cannot be carried out, or can only be carried out partially, for these claims.</p> <p>Claims searched completely :</p> <p>Claims searched incompletely :</p> <p>Claims not searched :</p> <p>Reason for the limitation of the search: see sheet C</p>			
Place of search		Date of completion of the search	Examiner
MUNICH		29 April 2002	Herrera, S
CATEGORY OF CITED DOCUMENTS			
<p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p>		<p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document</p>	

EPO FORM 1503 03.82 (P04C07)



European Patent
Office

**INCOMPLETE SEARCH
SHEET C**

Application Number
EP 01 30 3020

Claim(s) searched incompletely:
1-25

Reason for the limitation of the search:

The active ingredients in the present claims are defined by means of functional features, in the present claims, the mode of action. Whereas it is true that these definitions must be considered as clear, it is not possible to guarantee that the search is complete, since the the mode of action of an agent is not always given. The claims have been search on basis of the the mode of action and the exemplified agents have been searched as well.



European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT

Application Number
EP 01 30 3020

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
Y	FUJIMOTO SHIMPEI ET AL: "The novel insulinotropic mechanism of pimobendan: Direct enhancement of the exocytotic process of insulin secretory granules by increased Ca ²⁺ sensitivity in beta-cells." ENDOCRINOLOGY, vol. 139, no. 3, March 1998 (1998-03), pages 1133-1140, XP001070282 ISSN: 0013-7227 * abstract *	1-25	
Y	HÖHN H ET AL: "Potential Antidiabetic Agents. Pyrazolo[3,4-b]pyridines" JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, WASHINGTON, US, vol. 16, no. 12, 1973, pages 1340-1346, XP002097814 ISSN: 0022-2623 * abstract *	1-25	TECHNICAL FIELDS SEARCHED (Int.Cl.7)
Y	GRILL V ET AL: "INTERACTING EFFECTS OF SULFONYL UREAS AND GLUCOSE ON CYCLIC AMP METABOLISM AND INSULIN RELEASE IN PANCREATIC ISLETS OF THE RAT" JOURNAL OF CLINICAL INVESTIGATION, vol. 61, no. 5, 1978, pages 1346-1354, XP001070381 EN ISSN: 0021-9738 * abstract *	1-25	

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 01 30 3020

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

29-04-2002

Patent document cited in search report	Publication date	Patent family member(s)	Publication date	
WO 9836755	A	27-08-1998	AU 741215 B2	29-11-2001
			AU 5590898 A	09-09-1998
			BG 103671 A	28-04-2000
			BR 9714505 A	21-03-2000
			CN 1244801 A	16-02-2000
			CZ 9902892 A3	17-11-1999
			EE 9900345 A	15-02-2000
			EP 0957923 A1	24-11-1999
			HU 0001528 A2	28-11-2000
			JP 2001512478 T	21-08-2001
			NO 993982 A	18-08-1999
			NZ 336002 A	28-03-2002
			PL 335166 A1	10-04-2000
			SK 111899 A3	12-09-2000
			TR 9902033 T2	21-02-2000
			WO 9836755 A1	27-08-1998
			US 5972973 A	26-10-1999
			US 6011049 A	04-01-2000
			US 5859037 A	12-01-1999
			ZA 9801343 A	16-11-1998